ondasdechoque.org
PT-BR

Five-year course of foot ulcers · Single-group study · 2014

How do foot ulcers fare in the five years after shockwave?

In this five-year follow-up of 67 people treated with shockwave for long-standing foot ulcers, 40 of 72 ulcers had healed at one year, and 35 of 61 at five years among people still living. Over those years, 10 people died, most of them with diabetes, and 6 of 57 survivors had an amputation.

people with long-standing foot ulcers
67
shockwave sessions over 3 weeks
6
years of follow-up
5

Good to know: Single-group study; ulcers healed less often, and deaths were more common, in people with diabetes.

Wang CJ, Wu CT, Yang YJ, et al. J Surg Res, 2014 · Read the paper ↗

How this study worked

StartFollow-up67 people
One group was followed over time, without a comparison group. Each dot is one person.

Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.

The treatment

Shockwave

Shockwave, twice a week for 3 weeks

ShockwavesThe paper doesn’t say whether radial or focused
Pulses
500 per session · at least; more for bigger wounds (8 per cm² of wound plus a 1 cm border)
Strength
0.11mJ/mm² setting E2, as reported · 4 per second
Numbing
Not mentioned
Device
dermaPACE
Everyone also got
Ongoing wound and diabetes care as needed

Compared with: No comparison group; people with and without diabetes were compared

Settings are what each study used, not a prescription.

Who took part

67 people with long-standing foot ulcers (72 ulcers): 38 with diabetes and 29 without. At five years, 57 people with 61 ulcers remained.

Shockwave67 people

Side effects

Two people had a burning feeling that went away within 1–2 days. Over five years, 10 people died, 12 needed a skin graft or wound cleaning, and 6 had an amputation; the authors suggest the illness itself played a part.

All the numbers and the full appraisal

Every reported result

FROM THE FULL PAPER

The results, in numbers.

67 treated patients with 72 ulcers: 38 people/40 ulcers with diabetes and 29/32 without diabetes. At 5 years 57 survivors/61 ulcers remained.

Shockwave treatment67enrolled

Participant counts; outcome-specific denominators remain in each panel.

Completely healed ulcers1 reported outcome
01
1 year

Completely healed ulcers

Completely healed ulcers ulcers

Closure at one year: 40/72 ulcers. Ulcers, not people; all had received ESWT.

Analysis details and source

Closure at one year: 40/72 ulcers. Ulcers, not people; all had received ESWT.

Completely healed ulcers among survivors1 reported outcome
02
5 years

Completely healed ulcers among survivors

Completely healed ulcers among survivors ulcers

Closure at five years: 35/61 ulcers among survivors. Ten deaths excluded from late wound denominator.

Analysis details and source

Closure at five years: 35/61 ulcers among survivors. Ten deaths excluded from late wound denominator.

All-cause mortality1 reported outcome
03
5 years

All-cause mortality

All-cause mortality participants

Shockwave treatment10 / 67

Nine of 38 diabetics and 1/29 nondiabetics died; observational comparison.

Analysis details and source

Nine of 38 diabetics and 1/29 nondiabetics died; observational comparison.

Amputation among survivors1 reported outcome
04
5 years

Amputation among survivors

Amputation among survivors participants

Shockwave treatment6 / 57

Reported denominator excludes deaths; not a treatment-related harm estimate.

Analysis details and source

Reported denominator excludes deaths; not a treatment-related harm estimate.

Ulcer closure at three months1 reported outcome
05
3 months

Ulcer closure at three months

Ulcer closure at three months ulcers

27/72 ulcers closed: 8/40 in the diabetes subgroup and 19/32 without diabetes. All received shockwaves; this is not an untreated comparison.

Analysis details and source

27/72 ulcers closed: 8/40 in the diabetes subgroup and 19/32 without diabetes. All received shockwaves; this is not an untreated comparison.

Laser Doppler perfusion trajectory1 reported outcome
06
Before treatment, 6 weeks, 1 year and 5 years

Laser Doppler perfusion trajectory

Laser Doppler perfusion trajectory reported laser Doppler instrument units

Diabetes: baseline 0.50±0.20, six weeks 0.57±0.21, one year 0.65±0.28, five years 0.11±0.10. Without diabetes: 0.49±0.29, 0.55±0.25, 0.67±0.30 and 0.28±0.22, respectively. Five-year subgroup p=.04. These instrument measurements are not direct clinical benefit; no untreated control was included.

Analysis details and source

Diabetes: baseline 0.50±0.20, six weeks 0.57±0.21, one year 0.65±0.28, five years 0.11±0.10. Without diabetes: 0.49±0.29, 0.55±0.25, 0.67±0.30 and 0.28±0.22, respectively. Five-year subgroup p=.04. These instrument measurements are not direct clinical benefit; no untreated control was included.

How treatment was delivered
Reported protocol

dermaPACE, E 2 reported 0.11 mJ/mm², 4 Hz, minimum 500 impulses or expanded wound area× 8; twice/week× 3 weeks. Source energy differs from 2011 report; do not harmonize. Anesthesia not stated.

HARMS & TOLERABILITY

Two transient burning sensations resolved within 1–2 days. By five years, 10 patients had died, 12 had needed a skin graft or debridement and 6 had an amputation; the authors suggest the natural course of the disease may have contributed. Causes of death are not reported, and the study cannot attribute prevention or causation to ESWT.

LIMITS OF THE ANALYSIS

No standard-care concurrent control; survivorship changes denominators. The historical controls (149 patients with diabetic foot ulcers treated in 2004) are not described by case mix or follow-up time. Multiple ulcer observations may be correlated. QOL timing/comparator selection unclear. Wang disclosed Sanuwave advisory role; Chang Gung grants funded work. Table 3 prints 12/72 as 6.7%, although the raw fraction is 16.7%. The text describes 12 patients receiving skin grafts while wound tables use ulcer denominators; these units cannot be interchanged.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • No standard-care concurrent control; survivorship changes denominators. The historical controls (149 patients with diabetic foot ulcers treated in 2004) are not described by case mix or follow-up time. Multiple ulcer observations may be correlated. QOL timing/comparator selection unclear. Wang disclosed Sanuwave advisory role; Chang Gung grants funded work. Table 3 prints 12/72 as 6.7%, although the raw fraction is 16.7%. The text describes 12 patients receiving skin grafts while wound tables use ulcer denominators; these units cannot be interchanged.
Research review

Source-linked critical reading

Uncontrolled studies

Reading depthMaterial consulted
Technical source record

Full source read: body, methods, results, all six tables (the article has no figures), discussion and disclosures. The article lists no supplementary material.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Uncontrolled longitudinal follow-up of 67 treated patients with 72 ulcers, comparing diabetes subgroups; 57 survivors with 61 ulcers remained at five years.

Participants and setting

67 treated patients with 72 ulcers: 38 people/40 ulcers with diabetes and 29/32 without diabetes. At 5 years 57 survivors/61 ulcers remained.

Treatment delivered

All received six ESWT treatments and necessary ongoing wound/diabetes care.

What was compared

Diabetic versus nondiabetic prognosis; historical diabetic controls and a separate HBOT QOL sample were not randomized concurrent controls.

Outcomes and timing

Wound status was classified at three months, one year and five years. Laser Doppler measurements assessed perfusion at baseline, six weeks, one year and five years. Mortality and amputation were recorded separately from ulcer-level healing; late healing denominators exclude those who died.

Results in context

Complete healing 40/72 at 1 year and 35/61 at 5 years; the later denominator excludes 10 deaths. Diabetes 13/30 versus nondiabetes 22/31 ulcers healed at 5 years. Perfusion gains at 1 year declined by 5 years. Six of 57 survivors underwent amputation.

Harms and tolerability

Two transient burning sensations resolved within 1–2 days. By five years, 10 patients had died, 12 had needed a skin graft or debridement and 6 had an amputation; the authors suggest the natural course of the disease may have contributed. Causes of death are not reported, and the study cannot attribute prevention or causation to ESWT.

Limits and disclosures

No standard-care concurrent control; survivorship changes denominators. The historical controls (149 patients with diabetic foot ulcers treated in 2004) are not described by case mix or follow-up time. Multiple ulcer observations may be correlated. QOL timing/comparator selection unclear. Wang disclosed Sanuwave advisory role; Chang Gung grants funded work. Table 3 prints 12/72 as 6.7%, although the raw fraction is 16.7%. The text describes 12 patients receiving skin grafts while wound tables use ulcer denominators; these units cannot be interchanged.

Clinical applicability

Describes prognosis after treatment, not sustained causal benefit. Booster therapy is a hypothesis, not tested here.

What a next study should resolve

A controlled long-term study should jointly report healing, recurrence, amputation and death, account for multiple ulcers and competing mortality, and follow every originally enrolled patient.

THE ORIGINAL SOURCE

Read the original article.

Long-term outcomes of extracorporeal shockwave therapy for chronic foot ulcers

Wang CJ, Wu CT, Yang YJ, Liu RT, Kuo YR. · J Surg Res · 2014

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →